Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI oncological therapeutics, announced today that ...

Over 10,000 patients have been treated with sorafenib as single agent or in combination regimens. Sorafenib is US FDA approved for the treatment of advanced renal cell carcinoma and unresectable ...

As a single agent, it showed only modest activity, but in combination with chemotherapy it produced slightly better results. DTIC and sorafenib combination was evaluated in a multicenter ...

In 2020, the combination received accelerated approval ... as a second-line treatment for advanced HCC patients treated with sorafenib. In March 2025, BMS agreed to acquire 2seventy bio, the ...

During a Community Case Forum event, Stacey Stein, MD, discussed data guiding the use of current regimens for the treatment ...

a prevalent and deadly liver cancer in the U.S. CHECKMATE-9DW trial results showed improved median overall survival with the combination therapy compared to lenvatinib or sorafenib. The ...

The regulatory action was based on improvements in overall survival (OS) and overall response rate (ORR) demonstrated in the Phase III CheckMate-9DW trial, evaluating the combination in comparison to ...

Additionally, the combination treatment was associated with longer responses, with a median duration of response of 30.4 months. This compared with 12.9 months for lenvatinib or sorafenib.

Strategic insight into the Liver Cancer Treatment Market reveals a high-growth opportunity, especially in Asia-Pacific, driven by a rising patient pool and evolving healthcare infrastructure. However, ...